Novo Nordisk reported 4.96B in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
Bausch Health Companies USD 465M 135M Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Eli Lilly USD 249M 5.3M Jun/2025
GlaxoSmithKline 184M 22M Jun/2025
Merck USD 305M 8M Jun/2025
Novartis USD 289M 19M Jun/2025
Novo Nordisk 4.96B 225M Jun/2025
Pacira USD 3.82M 110K Jun/2025
Sanofi 148M 65M Jun/2025
Supernus Pharmaceuticals USD 0 0 Dec/2024